dopaminergic neuron replacement

Assets acting on this target.

Class
stem cell-derived dopaminergic neuron replacement therapy

Dopaminergic neuron replacement targets the loss of dopamine-producing neurons in the substantia nigra, a midbrain structure whose projections to the striatum (the nigrostriatal pathway) normally coordinate movement. In Parkinson's disease, progressive degeneration of these neurons reduces striatal dopamine, producing tremor, rigidity, and slowed movement. Conventional pharmacologic therapy supplies dopamine or its precursors systemically, but this approach is symptomatic and becomes less reliable as disease progresses, often accompanied by fluctuating drug levels and motor complications. Cell replacement therapy takes a different approach: rather than adding dopamine chemically, it aims to reconstitute the missing cell population itself. Autologous induced pluripotent stem cell (iPSC)-derived therapies reprogram a patient's own cells into a stem-cell-like state, then differentiate them into dopaminergic neuron precursors that are surgically implanted into the brain, with the intent that they mature, integrate into local circuitry, and provide a sustained, endogenously regulated source of dopamine. Because the cells originate from the patient, this strategy is intended to reduce the risk of immune rejection compared with donor-derived tissue. This mechanism is relevant chiefly to Parkinson's disease and other conditions marked by selective neuronal loss where restoring cellular function, not just neurotransmitter levels, is the underlying therapeutic goal.

By indication

Related mechanisms

dopaminergic neuron replacement drugs compared

7 drugs, stage by indication
7 drugs acting on dopaminergic neuron replacement: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
NouvNeu001iRegene Therapeutics Co., Ltd.cell therapyPhase 2Phase 2 in Parkinson's Disease
RNDP-001Kenai Therapeuticscell therapyPhase 1/2Phase 1/2 in Parkinson's Disease
TED-A9 (A9-DPC)S.Biomedicscell therapyPhase 1/2Phase 1/2 in Parkinson's Disease
XS-411XellSmart Bio-Pharmaceutical (Suzhou)cell therapyPhase 1/2Phase 1/2 in Parkinson's Disease
iPS-NSC cellsAllife Medical Science and Technologycell therapyPhase 1Phase 1 in Parkinson's Disease
SasineprocelAspen Neurosciencecell therapyPhase 1Phase 1 in Parkinson's Disease
UX-DA001Shanghai UniXell Biotechnology Co., Ltdcell therapyPhase 1Phase 1 in Parkinson's Disease

← all mechanisms